Publications by authors named "M Cornfeld"
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
Gynecol Oncol
July 2024
Article Synopsis
- Retifanlimab, a monoclonal antibody targeting programmed death 1, is being tested for safety and effectiveness in patients with recurrent microsatellite instability-high/mismatch repair deficient endometrial cancer.
- In a study involving 76 patients, half experienced significant side effects, with anemia and fatigue being the most common, but many also achieved positive treatment responses.
- The results indicate that retifanlimab is generally well tolerated and shows promising anti-tumor activity, with some patients having a progression-free survival of over a year.
Article Synopsis
- The POD1UM-203 study tested retifanlimab, a monoclonal antibody that targets PD-1, on patients with specific solid tumors that have had successful responses to immune checkpoint therapies in the past.
- A total of 121 patients with various cancers (melanoma, NSCLC, urothelial carcinoma, and renal cell carcinoma) were treated, showing overall response rates ranging from 23.5% to 40% across different cohorts.
- Results indicate that retifanlimab has durable anti-tumor effects and a safety profile similar to other PD-(L)1 inhibitors, supporting further investigation in solid tumors.
Article Synopsis
- A phase II study (POD1UM-202) evaluated the effectiveness of retifanlimab, a PD-1 targeting antibody, in patients with advanced or metastatic squamous carcinoma of the anal canal (SCAC) who had previously undergone platinum-based chemotherapy.
- * In the study involving 94 patients, the overall response rate was 13.8%, with one complete response and 12 partial responses, showing efficacy regardless of HIV/HPV status or PD-L1 expression.
- * Median progression-free survival was 2.3 months, and overall survival was 10.1 months, indicating that retifanlimab has meaningful antitumor activity and an acceptable safety profile in this hard-to-treat patient population.
This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.
View Article and Find Full Text PDFBackground: Langerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation of dendritic cells, and is also often upregulated in hematopoietic malignancies. A clinical response in an adult patient with LCH participating in the first-in-human trial of afuresertib prompted this prospective trial.
View Article and Find Full Text PDF